Recent studies demonstrated that Kyn can be found in high concentrations in the plasma of advanced-stage cancer patients and a high serum Kyn/Trp ratio correlates with poor prognosis after PD-1 blockade in several cancer types, including lung cancer, melanoma, and renal cell carcinomas11–13, while systemic Kyn depletion with a PEGylated Kyn-degrading enzyme led to cancer control in pre-clinical settings14. The gene discussed is PDCD1; the disease is melanoma.